Last reviewed · How we verify

Mometasone Furoate MDI 200 mcg

Organon and Co · FDA-approved active Small molecule Quality 2/100

Mometasone Furoate MDI 200 mcg is a Small molecule drug developed by Organon and Co. It is currently FDA-approved. Also known as: Asmanex.

Mometasone Furoate MDI 200 mcg, marketed by Organon and Co, holds a position in the respiratory therapy segment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameMometasone Furoate MDI 200 mcg
Also known asAsmanex
SponsorOrganon and Co
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mometasone Furoate MDI 200 mcg

What is Mometasone Furoate MDI 200 mcg?

Mometasone Furoate MDI 200 mcg is a Small molecule drug developed by Organon and Co.

Who makes Mometasone Furoate MDI 200 mcg?

Mometasone Furoate MDI 200 mcg is developed and marketed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

Is Mometasone Furoate MDI 200 mcg also known as anything else?

Mometasone Furoate MDI 200 mcg is also known as Asmanex.

What development phase is Mometasone Furoate MDI 200 mcg in?

Mometasone Furoate MDI 200 mcg is FDA-approved (marketed).

Related